ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance

PLoS Genetics

Volumn 10, Issue 6, 2014, Pages

  Wang, Zhiqiang ^a   Liu, Zheng ^a   Wu, Xiwei ^a   Chu, Su ^a   Wang, Jinhui ^a   Yuan, Hongfeng ^a   Roth, Mendel ^a   Yuan, Yate Ching ^a   Bhatia, Ravi ^a   Chen, WenYong ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD38 ANTIGEN; DASATINIB; IMATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE NUCLEOSIDASE; NILOTINIB; RETINOIC ACID; SIRTUIN 1; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SIRT1 PROTEIN, HUMAN; THIAZOLE DERIVATIVE;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BCR ABL GENE; BONE MARROW CULTURE; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL SURFACE; CHROMOSOME 4; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; DRUG EXPOSURE; ENZYME INHIBITION; EXOME; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC VARIABILITY; IN VITRO STUDY; KARYOTYPING; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; MUTAGENESIS; NUCLEOTIDE SEQUENCE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; FLOW CYTOMETRY; GENETICS; HUMAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PATHOLOGY; POINT MUTATION; TUMOR CELL LINE;

ANTIGENS, CD38; APOPTOSIS; BENZAMIDES; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; POINT MUTATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SIRTUIN 1; THIAZOLES; TRETINOIN;

EID: 84903459000     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1004414     Document Type: Article

References (62)

1. Melo JV, Barnes DJ, (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7: 441-453.
2. Deininger MW, Druker BJ, (2003) Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 55: 401-423.
3. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, et al. (2003) Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101: 4701-4707.
4. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, et al. (2006) Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A 103: 16870-16875.
5. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
6. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
7. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542-2551.
8. Shah NP, Tran C, Lee FY, Chen P, Norris D, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
9. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, et al. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531-2541.
10. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, et al. (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16: 401-412.
11. Yuan H, Wang Z, Gao C, Chen W, Huang Q, et al. (2010) BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J Biol Chem 285: 5085-5096.
12. Wang Z, Yuan H, Roth M, Stark JM, Bhatia R, et al. (2013) SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene 32: 589-598.
13. Yuan H, Wang Z, Zhang H, Roth M, Bhatia R, et al. (2012) Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model. Carcinogenesis 33: 285-293.
14. Chen WY, Yuan H, Wang Z (2011) De novo acquisition of BCR-ABL mutations for CML acquired resistance. In: Koschmieder S, Krug U, editors. Myeloid Leukemia: Basic Mechanisms of Leukemogenesis INTECH. pp. 69-84.
15. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, et al. (1997) All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337: 1021-1028.
16. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, et al. (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324: 1385-1393.
17. Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, et al. (2008) Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 88: 841-886.
18. Radich JP, Dai H, Mao M, Oehler V, Schelter J, et al. (2006) Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 103: 2794-2799.
19. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
20. Huang F, Reeves K, Han X, Fairchild C, Platero S, et al. (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67: 2226-2238.
21. Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, et al. (2004) Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 10: 272-284.
22. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, et al. (2008) High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27: 565-573.
23. Dash AB, Williams IR, Kutok JL, Tomasson MH, Anastasiadou E, et al. (2002) A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci U S A 99: 7622-7627.
24. Kroon E, Thorsteinsdottir U, Mayotte N, Nakamura T, Sauvageau G, (2001) NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. Embo J 20: 350-361.
25. Takeda A, Goolsby C, Yaseen NR, (2006) NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34+ hematopoietic cells. Cancer Res 66: 6628-6637.
26. Graham SM, Vass JK, Holyoake TL, Graham GJ, (2007) Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 25: 3111-3120.
27. Kubonishi I, Miyoshi I, (1983) Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning 1: 105-117.
28. Drach J, McQueen T, Engel H, Andreeff M, Robertson KA, et al. (1994) Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha. Cancer Res 54: 1746-1752.
29. Lamkin TJ, Chin V, Varvayanis S, Smith JL, Sramkoski RM, et al. (2006) Retinoic acid-induced CD38 expression in HL-60 myeloblastic leukemia cells regulates cell differentiation or viability depending on expression levels. J Cell Biochem 97: 1328-1338.
30. Wiernik PH, Dutcher JP, Paietta E, Hittelman WN, Vyas R, et al. (1991) Treatment of promyelocytic blast crisis of chronic myelogenous leukemia with all trans-retinoic acid. Leukemia 5: 504-509.
31. Nilsson B, Olofsson T, Olsson I, (1984) Myeloid Differentiation in Liquid Cultures of Cells from Patients with Chronic Myeloid-Leukemia- Effects of Retinoic Acid and Indomethacin. Experimental Hematology 12: 91-99.
32. Aksoy P, White TA, Thompson M, Chini EN, (2006) Regulation of intracellular levels of NAD: a novel role for CD38. Biochem Biophys Res Commun 345: 1386-1392.
33. Aksoy P, Escande C, White TA, Thompson M, Soares S, et al. (2006) Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. Biochem Biophys Res Commun 349: 353-359.
34. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, et al. (2005) Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105: 2093-2098.
35. Schemionek M, Elling C, Steidl U, Baumer N, Hamilton A, et al. (2010) BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 115: 3185-3195.
36. Bruns I, Czibere A, Fischer JC, Roels F, Cadeddu RP, et al. (2009) The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia 23: 892-899.
37. Yuan H, Wang Z, Li L, Zhang H, Modi H, et al. (2012) Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 119: 1904-1914.
38. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26.
39. Collins SJ, (2002) The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia 16: 1896-1905.
40. Purton LE, Bernstein ID, Collins SJ, (2000) All-trans retinoic acid enhances the long-term repopulating activity of cultured hematopoietic stem cells. Blood 95: 470-477.
41. Chen Z, Wang ZY, Chen SJ, (1997) Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther 76: 141-149.
42. Dutcher JP, Lee S, Gallagher RE, Makary AZ, Hines JD, et al. (2005) Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993). Leuk Lymphoma 46: 377-385.
43. Egyed M, Kollar B, Rumi G, Keller E, Vass J, et al. (2003) Effect of retinoic acid treatment on cytogenetic remission of chronic myeloid leukaemia. Acta Haematol 109: 84-89.
44. Cortes J, Kantarjian H, O'Brien S, Beran M, Estey E, et al. (1997) A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Leukemia 11: 929-932.
45. Adamson PC, (1996) All-Trans-Retinoic Acid Pharmacology and Its Impact on the Treatment of Acute Promyelocytic Leukemia. Oncologist 1: 305-314.
46. Peng B, Lloyd P, Schran H, (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44: 879-894.
47. Alessio M, Roggero S, Funaro A, De Monte LB, Peruzzi L, et al. (1990) CD38 molecule: structural and biochemical analysis on human T lymphocytes, thymocytes, and plasma cells. J Immunol 145: 878-884.
48. Terstappen LW, Huang S, Safford M, Lansdorp PM, Loken MR, (1991) Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood 77: 1218-1227.
49. Kapil Mehta FM, editor (2000) Human CD38 and Related Molecules: Chemical Immunology.
50. Prus E, Fibach E, (2003) Retinoic acid induction of CD38 antigen expression on normal and leukemic human myeloid cells: relationship with cell differentiation. Leuk Lymphoma 44: 691-698.
51. Houtkooper RH, Pirinen E, Auwerx J, (2012) Sirtuins as regulators of metabolism and healthspan. Nature Reviews Molecular Cell Biology 13: 225-238.
52. Morris BJ, (2013) Seven sirtuins for seven deadly diseases of aging. Free Radical Biology and Medicine 56: 133-171.
53. Roth M, Chen WY, (2013) Sorting out functions of sirtuins in cancer. Oncogene 33 (13):: 1609-20 doi:10.1038/onc.2013.120.
54. Yuan H, Su L, Chen WY, (2013) The emerging and diverse roles of sirtuins in cancer: a clinical perspective. OncoTargets & Therapy 6: 1399-1416.
55. Wang Z, Chen WY, (2013) Emerging Roles of SIRT1 in Cancer Drug Resistance. Genes Cancer 4: 82-90.
56. Li L, Wang L, Wang Z, Ho Y, McDonald T, et al. (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21: 266-281.
57. Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, et al. (2013) Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 121: 4175-4183.
58. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, et al. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94: 1840-1847.
59. Bergthorsdottir S, Gallagher A, Jainandunsing S, Cockayne D, Sutton J, et al. (2001) Signals that initiate somatic hypermutation of B cells in vitro. J Immunol 166: 2228-2234.
60. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, et al. (2005) Dynamics of chronic myeloid leukaemia. Nature 435: 1267-1270.
61. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, et al. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486: 537-540.
62. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z, (2009) Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25: 2865-2871.